WO2025158385 - PEGYLATED IL-2 FOR SUPPRESSING ADAPTIVE IMMUNE RESPONSE TO GENE THERAPY
National phase entry is expected:
Publication Number
WO/2025/158385
Publication Date
31.07.2025
International Application No.
PCT/IB2025/050828
International Filing Date
24.01.2025
Title **
[English]
PEGYLATED IL-2 FOR SUPPRESSING ADAPTIVE IMMUNE RESPONSE TO GENE THERAPY
[French]
IL-2 PÉGYLÉ POUR SUPPRIMER UNE RÉPONSE IMMUNITAIRE ADAPTATIVE À UNE THÉRAPIE GÉNIQUE
Applicants **
GENZYME CORPORATION
Inventors
CHOUDHURY, Sourav Roy
MOTWANI, Mona
MUELLER, Christian
PARK, Mincheol
GWALANI, Lavesh
Priority Data
63/625,113
25.01.2024
US
63/641,189
01.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5924 | |
| EPO | Filing, Examination, Granting | 79970 | |
| Japan | Filing, Examination, Granting | 4425 | |
| South Korea | Filing, Examination, Granting | 6489 | |
| USA | Filing, Examination, Granting | 22340 |
Total:
119,148
Contact Us
Abstract[English]
The disclosure relates to methods of delivering a gene therapy agent to a subject, treating an individual in need of a gene therapy agent, increasing expression of a gene therapy agent, reducing an immune response to a gene therapy agent, and preventing immune-related adverse events in a subject by administering a gene therapy agent and an IL-2 conjugate to the subject. The IL-2 conjugate has at least one amino acid residue replaced by an unnatural amino acid linked to a conjugating moiety. The disclosure further relates to methods of selecting a subject for treatment with a gene therapy agent and an IL-2 conjugate.[French]
La divulgation concerne des procédés d'administration d'un agent de thérapie génique à un sujet, de traitement d'un individu ayant besoin d'un agent de thérapie génique, d'augmentation de l'expression d'un agent de thérapie génique, de réduction d'une réponse immunitaire à un agent de thérapie génique, et de prévention d'événements indésirables liés à l'immunité chez un sujet par l'administration d'un agent de thérapie génique et d'un conjugué d’IL-2 au sujet. Le conjugué d'IL-2 a au moins un résidu d'acide aminé remplacé par un acide aminé non naturel lié à une fraction de conjugaison. La divulgation concerne en outre des procédés de sélection d'un sujet pour un traitement avec un agent de thérapie génique et un conjugué d’IL-2.